Showing 1 - 6 results of 6 for search 'Karel Indrak', query time: 0.03s Refine Results
  1. 1
    Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports

    Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports by Peter Rohon, Jana Vondrakova, Anna Jonasova, Milena Holzerova, Marie Jarosova, Karel Indrak

    Published 2012-01-01
    Get full text
    Article
  2. 2
    Infectious complications of induction treatment for acute myeloid leukaemia using the "7 + 3" protocol without antibiotic prophylaxis - 15 years of experience of one clinical site

    Infectious complications of induction treatment for acute myeloid leukaemia using the "7 + 3" protocol without antibiotic prophylaxis - 15 years of experience of one clinical site by Martin Cernan, Tomas Szotkowski, Jaromir Hubacek, Milan Kolar, Edgar Faber, Karel Indrak, Tomas Papajik

    Published 2023-09-01
    Get full text
    Article
  3. 3
    Spontaneous splenic rupture in a patient with acute promyelocytic leukaemia during induction chemotherapy

    Spontaneous splenic rupture in a patient with acute promyelocytic leukaemia during induction chemotherapy by Adam Kuba, Tomas Szotkowski, Peter Rohon, Edgar Faber, Peter Turcsanyi, Jaromir Hubacek, Milena Holzerova, Vojtech Prasil, Marie Jarosova, Karel Indrak

    Published 2015-06-01
    Get full text
    Article
  4. 4
    Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

    Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group by Frédéric Baron, Stefan Suciu, Sergio Amadori, Petra Muus, Heinz Zwierzina, Claudio Denzlinger, Michel Delforge, Antoine Thyss, Dominik Selleslag, Karel Indrak, Gert Ossenkoppele, Theo de Witte

    Published 2012-04-01
    Get full text
    Article
  5. 5
    Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.

    Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile. by Anna Kreutzman, Peter Rohon, Edgar Faber, Karel Indrak, Vesa Juvonen, Veli Kairisto, Jaroslava Voglová, Marjatta Sinisalo, Emília Flochová, Jukka Vakkila, Petteri Arstila, Kimmo Porkka, Satu Mustjoki

    Published 2011-01-01
    Get full text
    Article
  6. 6
    Evaluation of 5‐year imatinib treatment of 458 patients with CP‐CML in routine clinical practice and prognostic impact of different BCR‐ABL cutoff levels

    Evaluation of 5‐year imatinib treatment of 458 patients with CP‐CML in routine clinical practice and prognostic impact of different BCR‐ABL cutoff levels by Hana Klamová, Kateřina Machová Poláková, Jan Mužík, Zdeněk Ráčil, Daniela Žáčková, Kateřina Steinerová, Michal Karas, Edgar Faber, Eva Demečková, Zuzana Michalovičová‐Sninská, Jaroslava Voglová, Ľudmila Demitrovičová, Eva Mikušková, Elena Tóthová, Juraj Chudej, Imrich Markuljak, Eduard Cmunt, Jana Moravcová, Dana Dvořáková, Kyra Michalová, Marie Jarošová, Markéta Marková Šťastná, Petr Cetkovský, Ladislav DuŠek, Vladimír Koza, Marek Trněný, Karel Indrák

    Published 2013-04-01
    Get full text
    Article

Search Tools: